The content is available as a PDF (273.7 KB).
editorial . 2021 May 17:ciab459. doi: 10.1093/cid/ciab459
Cost-effectiveness of tocilizumab in severe COVID-19: to see or not to see
Lauren Pischel
1,2, George Goshua
3,4,✉
Lauren Pischel, M.D
1Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA
2Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA
Find articles by Lauren Pischel
George Goshua, M.D
3Section of Hematology, Yale School of Medicine, New Haven, Connecticut, USA
4Department of Health Policy and Management, Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA
Find articles by George Goshua
1Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA
2Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA
3Section of Hematology, Yale School of Medicine, New Haven, Connecticut, USA
4Department of Health Policy and Management, Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA
✉
Corresponding Author Contact: Full Name: George Goshua, 333 Cedar Street, New Haven CT 06520, Email: george.goshua@yale.edu
Received 2021 May 9.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC8194546 PMID: 33999992
See "Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality" in volume 73 on page 2116.
See commentary "Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality" in volume 73 on page 2116.